ストックスクリーナーアプリを入手
4.10
2.15%
-0.09
アフターアワーズ：
4.19
0.09
+2.20%
Immuneering Corp (IMRX) 最新ニュース
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) - Minichart
According to a document submitted to the U.S. Securities and Exchange Commission, as of April 24, 2026, biotechnology company Immuneering Corp observed a median overall survival of 17.3 months in the intent-to-treat population of its 320 mg dosage gro - Bitget
[8-K] Immuneering Corp Reports Material Event - Stock Titan
Immuneering stock maintained at Outperform by Oppenheimer on survival data - Investing.com South Africa
Immuneering reports median survival data from pancreatic trial - Investing.com
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib - Quiver Quantitative
Pancreatic cancer drug combo shows 17.3-month survival in trial - Stock Titan
Immuneering Corp stock (US45255L1089): IMRX trades around 5.36 USD ahead of key June data - AD HOC NEWS
Immuneering Corporation (IMRX) Slides 2.2% as Pressure Mounts Near Key SupportBreakout Stock Alerts - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentCFO Commentary Report - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower Loss Exceeds Expectations as Pipeline Progress ContinuesPre-Announcement Alert - newsline.com
MEK inhibitor delivers 17.3-month OS for pancreatic cancer - BioWorld News
IMRX Jumps As Immuneering Extends Cash Runway And Trial Pipeline - StocksToTrade
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy - The Manila Times
Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 - Quiver Quantitative
Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival - Stock Titan
Immuneering Corp stock (US45255L1089): clinical updates keep biotech investors watching - AD HOC NEWS
Immuneering Corporation (IMRX) Stock: Jumps +3.89%, Approaching $5.33 2026-05-20Diamond Pattern - The Legal Advocate
Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes - BioSpace
Immuneering stock (US45255L1089): Insider buying puts the biotech back in focus - AD HOC NEWS
Immuneering Corporation Reports Q1 2026 Financial Results and Announces Positive Phase 2a Pancreatic Cancer Trial Data – Minichart - Minichart
Immuneering Corp Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immuneering Hikes on Q1 Figures - Baystreet.ca
Immuneering to present pancreatic cancer trial data at ASCO - Investing.com
Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary - TradingView
Immuneering (IMRX) advances atebimetinib into MAPKeeper 301 Phase 3 - Stock Titan
Immuneering reports Q1 2026 net loss $13.5M, $198.6M cash runway into 2029 - TradingView
Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX) - Stock Titan
Pancreatic cancer patient gets 27 months progression-free on Immuneering drug - Stock Titan
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corp stock (US45255L1089): Q4 beat and 174% YTD surge - AD HOC NEWS
TradingKey - TradingKey
The one question every Immuneering Corporation (IMRX) investor should ask (Smart Money Flows) 2026-05-11Crowd Risk Alerts - newser.com
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors - TipRanks
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - Yahoo Finance
Insider Buyers At Immuneering Sitting On US$361k Profit - Sahm
Immuneering Corp (IMRX) Stock Price, Quote, News & History - Benzinga
IMRX (Immuneering Corporation) shares rise 6.13 percent after reporting narrower than expected Q4 2025 per share loss.Return On Equity - newsline.com
Immuneering brings 55-patient pancreatic survival update to ASCO oral - Stock Titan
Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification - Stock Titan
Immuneering (IMRX) Reveals Promising Genetic Data at Upcoming AA - GuruFocus
Immuneering presents genetic data on atebimetinib resistance - Investing.com
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - The Manila Times
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):